Arcturus data answers key investor question, says Guggenheim

Guggenheim analyst Seamus Fernandez says the pre-print of Arcturus Therapeutics (ARCT) and collaborators’ Phase 3 Japan trial evaluating safety and immunogenicity of ARCT-154 versus Pfizer’s (PFE) Comirnaty as a COVID booster answers the key investor question. This is first data seen that demonstrates ARCT-154 is at least as good as Pfizer’s Wuhan Comirnaty with a monovalent vaccine, and validates that the technology generates a robust antibody response, the analyst tells investors in a research note. The firm also highlights that ARCT-154 showed an improved local reactogenicity profile attributed to its lower dose. It believes investors continue to undervalue the prospects of not only ARCT-154 but also for the broader platform of vaccines Arcturus is now partnered with CSL. Guggenheim keeps a Buy rating on the shares.